HDL Therapeutics HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis. | ![]() ReShape Lifesciences ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. | ![]() ElectroCore ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders. | ||
Founding Date | Founding Date 2009 | Founding Date 2002 | Founding Date 2005 | Founding Date N/A |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Vero Beach, US HQ | Locations San Clemente, US HQ San Clemente, US | Locations Rockaway, US HQ Parksville, CA Geretsried, DE Hamburg, DE Yeadon, GB Bernards, US | Locations Dublin, IE HQ Dublin, IE |
Employees | Employees 7 | Employees 4348% decrease | Employees 5144% decrease | Employees 838% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 3 m | Valuation ($) 71.2 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $11.3m (FY, 2020) | Revenue (est.) $32m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $5m (FY, 2020) | Cost of goods $4.2m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $6.3m (FY, 2020) | Gross profit $27.8m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($21.6m) (FY, 2020) | Net income ($14m) (FY, 2025) | Net income N/A |
Funding | ||||
Latest funding round | Latest funding round $ 3m (almost 7 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 7.5m (about 10 years ago) |
Total funding raised | Total funding raised $ 7.4m | Total funding raised N/A | Total funding raised $ 127m | Total funding raised $ 7.5m |

ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.
View company
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
View company
FIRE1 focuses on developing novel remote monitoring devices.
View company